GH Research (GHRS) Other Accumulated Expenses (2021 - 2025)
GH Research's (GHRS) quarterly Other Accumulated Expenses came in at $4.2 million in Q4 2025, down 14.42% year-on-year from $5.0 million in Q4 2024, and down 31.65% quarter-over-quarter from $6.2 million in Q3 2025.
GH Research (GHRS) Other Accumulated Expenses (2021 - 2025) Analysis & Trends
GH Research's Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $4.2 million for Q4 2025.
- On a quarterly basis, Other Accumulated Expenses fell 14.42% year-over-year to $4.2 million in Q4 2025; TTM through Dec 2025 was $4.2 million, a 14.42% decrease from a year earlier, with the FY2025 full-year figure at $4.2 million, down 14.42% from the prior year.
- Other Accumulated Expenses eased to $4.2 million in Q4 2025 per GHRS's latest filing, from $6.2 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $6.6 million in Q3 2024 and bottomed at $819000.0 in Q3 2021.
- The 5-year median for Other Accumulated Expenses is $3.4 million (2023), against an average of $3.7 million.
- Across the five-year window, Other Accumulated Expenses surged 143.37% in 2023 and dropped 14.42% in 2025, its largest moves.
- Year by year, Other Accumulated Expenses stood at $3.0 million in 2021, then fell by 10.22% to $2.7 million in 2022, then advanced by 7.09% to $2.9 million in 2023, then jumped by 72.84% to $5.0 million in 2024, then declined by 14.42% to $4.2 million in 2025.
- Per Business Quant, the three latest GHRS Other Accumulated Expenses figures stand at $4.2 million (Q4 2025), $6.2 million (Q3 2025), and $6.2 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn |
| 10 | GH Research | 1.72 Bn | 1.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.24 Mn |
| Sep 30, 2025 | 6.21 Mn |
| Jun 30, 2025 | 6.16 Mn |
| Mar 31, 2025 | 4.81 Mn |
| Dec 31, 2024 | 4.96 Mn |
| Sep 30, 2024 | 6.57 Mn |
| Jun 30, 2024 | 4.97 Mn |
| Mar 31, 2024 | 3.39 Mn |
| Dec 31, 2023 | 2.87 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Jun 30, 2023 | 3.38 Mn |
| Mar 31, 2023 | 3.38 Mn |
| Dec 31, 2022 | 2.68 Mn |
| Sep 30, 2022 | 1.64 Mn |
| Jun 30, 2022 | 1.39 Mn |
| Mar 31, 2022 | 2.52 Mn |
| Dec 31, 2021 | 2.98 Mn |
| Sep 30, 2021 | 819,000.00 |